CEO’s Recent Share Sale Signals Strategic Rebalance, Not Panic
Insider sales by Cognition Therapeutics’ CEO signal disciplined portfolio rebalancing amid Alzheimer’s pipeline uncertainty—watch for clinical milestones that could spark a price rebound.
6 minutes to read